NCT00454883View on ClinicalTrials.gov

Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders.

CompletedOBSERVATIONAL

Enrollment

379

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

December 31, 2007

Study Completion Date

December 31, 2007

Conditions

Affective Psychosis, BipolarManiaManic-Depressive Psychosis

Interventions

DRUG

ziprasidone

Ziprasidone 40 mg twice daily taken with food. Daily dosage may subsequently be adjusted on the basis of individual clinical status up to a maximum of 80 mg twice daily. If indicated, the maximum recommended dose may be reached as early as day 3 of treatment.

All Listed Sponsors

lead

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

INDUSTRY

NCT00454883 - Non-interventional Study of Ziprasidone in the Treatment of Bipolar and Schizoaffective Disorders. | Biotech Hunter | Biotech Hunter